All News

Erythema-based criteria miss skin of color, urging ROSCO phenotyping to improve diagnostic equity in dermatology.

Mayo Clinic case-control study links higher birth weight and childhood obesity to greater non-Hodgkin lymphoma risk, while longer breastfeeding may lower odds.

AI in myeloproliferative neoplasms can grade marrow fibrosis and predict survival, but authors say prospective, outcome-focused trials are needed first.

Costs of multimorbidity in older adults are climbing faster than its disability toll, and study authors say policy should look past single-disease programs.

October's FDA approvals included the introduction of 5 non-oncology treatment options across specialties.

PBM reform, Medicare Advantage exits, and the 340B rebate pilot are reshaping drug access. Here is what payers need to know heading into 2027.

Bipolar disorder often goes undiagnosed for years, and clinicians need to separate mood episodes from normal emotions and keep patients on treatment.

A phase 4 study found 69% of patients with OAB were consistently satisfied with vibegron at 12 months, with exploratory persistence of 59.8%.

Two machine learning models identifies MASLD in lean adults using 8 routine clinical measurements.

Meta-analysis suggests off-label upadacitinib drives major alopecia areata hair regrowth and SALT score gains, but phase 3 trials show lower responses.

Bipolar disorder can take 5 to 10 years to diagnose, and missing it can harm patients’ jobs, relationships, finances, and health.

Elagolix 150 mg was noninferior to dienogest 2 mg for reducing moderate-to-severe endometriosis pain in a phase 3 trial of 230 women in India.

Initial frontal fibrosing alopecia treatment was largely similar in Black and White patients, though tetracycline use was higher in Black patients.

Nearly half of patients with chronic HBV or HCV also had MASLD, tied to worse fatigue and quality of life.

Reductions in antibody function, not IgG titers, distinguishes efgartigimod responders in myasthenia gravis.

HHS does not intend to take enforcement action against pharmacies compounding BPC-157 and 5 other unapproved peptides if they meet 10 conditions.

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

Early modeling put sickle cell gene therapy coverage near 11 cents per member per month.

A clinical-note analysis of more than 1000 patients found rising off-label BPC-157 use for pain and healing, with outcomes unproven.

Frailty, but not HIV serostatus, is tied to more severe lower urinary tract symptoms in adults with and at risk for HIV, a cross-sectional study finds.

About one quarter of patients with overactive bladder were taking their initial oral regimen at nearly 3 years, yet most reported symptom improvement.

Claims data show evidence of HIV virus in 5 of 2913 long-acting cabotegravir users and higher adherence vs oral therapy.

Mirabegron was not tied to higher obesity-related neoplasm risk vs antimuscarinics in overactive bladder, but all-cause mortality was higher.

Experts at AMCP Nexus say biosimilar launches should prompt payers to revisit step therapy and measure value beyond market share.

Telehealth surpasses out-of-state travel for abortion care in total-ban states in 2025, and a second study suggests telehealth and clinic patients differ.

UAB experts said new bladder cancer, myeloma, and lung cancer therapies are changing care, but access and costs remain barriers.

Three experts apply policy, pharmacy operations, and member-level lenses to the same prescriptions to show why cost at the counter decides adherence.

Claims data also tied the combination to better adherence and fewer hospital admissions, including in bipolar I disorder, vs olanzapine alone.